Synmosa has the best low-humidity Effervescent Tablet manufacturing facility in Taiwan.
Product development and analysis of Synmosa's unique technological platform of HFA MDI (Metered Dose Inhaler) complies with the latest international regulatory requirements.
The unique formulas enable the liquid medication to remain longer in the nasal cavity and the time of drug release.
The Synmosa Biopharma Group Hormone Plant was established in May 2011, certified with PICIS GMP compliance.
From manufacturing to packaging, granules are produced in areas in compliance with PIC/S GMP.